CareLit · DOI-Nachweis · Geburtshilfe und Frauenheilkunde
Molecular basis and possibilities for modulation of resistance to anti-HER2 therapy
DOI 10.1055/s-0028-1121884
Bibliografische Angaben
Nachweis in CareLit
Autor:innenN Harbeck
ZeitschriftGeburtshilfe und Frauenheilkunde
Ausgabe02/2009
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
In breast cancer, targeted therapy is becoming increasingly important. Next to the oldest targeted therapy in breast cancer, i.e. endocrine therapy, two novel targeted agents are already approved for use in HER2 positive breast cancer: the monoclonal antibody trastuzumab (Herceptin®) is approved for adjuvant therapy as well as for metastatic disease (MBC). The small molecule lapatinib (Tyverb®) can be used in MBC if…
Zitieren
Zitierempfehlung
N Harbeck (2009) Molecular basis and possibilities for modulation of resistance to anti-HER2 therapy. Geburtshilfe und Frauenheilkunde (02). https://doi.org/10.1055/s-0028-1121884
Mit CareLit weiterarbeiten